Eremid Research Services has been established as the new name for the commercial arm of the 501(c)(3) non-profit, research organization - DHMRI. Eremid continues to specialize in the provision of genomics, metabolomics, NMR and vivarium research services, with dedicated expertise and cutting-edge instrumentation essential to furthering scientific understanding in areas including Human Health, Food & Nutrition, and AgBiotech.
As a genomics laboratories in North America, Eremid provides instrumentation and research expertise in genomics, transcriptomics, epigenetics, and bioinformatics, using novel and customized methods, assays, and protocols to suit a client’s exact needs. Eremid’s metabolomics team provides comprehensive investigation of metabolites and metabolism, supporting clients with study design, sample extraction, analysis, and data visualization and interpretation. The company’s laboratories are equipped with multiple mass spectrometers and nuclear magnetic resonance (NMR) platforms, including an ultra-high field 950 MHz NMR spectrometer, capable of characterizing small molecules, impurities, and metabolites at high resolution, even at very low concentrations.
“Working with Eremid has been a pleasure. We received excellent data with a very fast turnaround and appreciated the attentive and helpful project management,” Steve Watkins, CEO, BCD Biosciences said.
“The relaunch of our established services under the Eremid brand marks a significant new phase in the development of our facility, at a time when companies in the food, agriculture, and health sectors are increasingly seeing the value of accessing the expertise of dedicated contract research teams. Eremid has one of the best-equipped labs in North America, but what really sets us apart is our multi-omics expertise, and our customized, collaborative project design. By focusing on the science at hand and understanding the customer need, we deliver data that enables companies to develop products with improved characteristics, and enhanced societal and monetary value,” Julian Abery, Eremid’s Chief Business Officer said.